Targeting histone deacetylases for cancer therapy: Trends and challenges

• Published in: Acta pharmaceutica Sinica. B Vol. 13; no. 6; pp. 2425 - 2463
• Main Authors: Liang, Tao, Wang, Fengli, Elhassan, Reham M., Cheng, Yongmei, Tang, Xiaolei, Chen, Wengang, Fang, Hao, Hou, Xuben
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.06.2023; Elsevier
• Subjects: Combination therapy; HDACs; Multitarget agent; Oncogenesis; PROTAC; Review; Selective inhibitor; Multitarget agent; Oncogenesis; HDACs; Selective inhibitor; Combination therapy; PROTAC

Dysregulation of histone deacetylases (HDACs) is closely related to tumor development and progression. As promising anticancer targets, HDACs have gained a great deal of research interests and two decades of effort has led to the approval of five HDAC inhibitors (HDACis). However, currently traditio...